U.S. Court Finds Novo Nordisk Prandin Diabetes Drug Patent Invalid

A U.S. appeals court has decided that Novo Nordisk’s patent on Prandin — a diabetes drug used in combination with metformin — is invalid, thus allowing generic manufacturers to begin making lower-cost copies of the drug.
Reuters